GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Forms of GSK598809 Capsules.
- Conditions
- Substance Dependence
- Interventions
- Drug: GSK598809 new formulationDrug: GSK598809 old formulation
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00728897
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00728052
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
GSK372475 PK Study in Healthy Volunteers
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 66
- Registration Number
- NCT00728208
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Immunogenicity and Safety of GSK Biologicals' FluLaval® TF
- Conditions
- Influenza
- Interventions
- Biological: FluLaval® TF
- First Posted Date
- 2008-08-04
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 110
- Registration Number
- NCT00727428
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 74
- Registration Number
- NCT00726323
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
GSK1349572 Drug Interaction With Tenofovir
- Conditions
- Healthy Subjects
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00726336
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
- Conditions
- Neoplasms, Head and Neck
- Interventions
- Drug: GSK1363089 (foretinib)
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT00725764
- Locations
- 🇺🇸
GSK Investigational Site, Morgantown, West Virginia, United States
Study of GSK1363089 in Metastatic Gastric Cancer
- Conditions
- Neoplasms, Gastrointestinal Tract
- Interventions
- Drug: GSK1363089 (formerly XL880)
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 74
- Registration Number
- NCT00725712
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Leukaemia, Myelocytic, Acute
- Interventions
- Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT00725283
- Locations
- 🇫🇷
GSK Investigational Site, Grenoble cedex 9, France
GSK706769/KALETRA Drug-drug Interaction Study
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: GSK706769 & KALETRA
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 17
- Registration Number
- NCT00723775
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States